A Cyclic Peptide Inhibitor of HIF-1 Heterodimerization That Inhibits Hypoxia Signaling in Cancer Cells

Citations Over TimeTop 10% of 2013 papers

Abstract

Hypoxia inducible factor-1 (HIF-1) is a heterodimeric transcription factor that acts as the master regulator of cellular response to reduced oxygen levels, thus playing a key role in the adaptation, survival, and progression of tumors. Here we report cyclo-CLLFVY, identified from a library of 3.2 million cyclic hexapeptides using a genetically encoded high-throughput screening platform, as an inhibitor of the HIF-1α/HIF-1β protein-protein interaction in vitro and in cells. The identified compound inhibits HIF-1 dimerization and transcription activity by binding to the PAS-B domain of HIF-1α, reducing HIF-1-mediated hypoxia response signaling in a variety of cell lines, without affecting the function of the closely related HIF-2 isoform. The reported cyclic peptide demonstrates the utility of our high-throughput screening platform for the identification of protein-protein interaction inhibitors, and forms the starting point for the development of HIF-1 targeted cancer therapeutics.

Related Papers

• → Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications(2017)110 cited
• → The Emergence of Cyclic Peptides: The Potential of Bioengineered Peptide Drugs(2014)38 cited
• → Peptide oligomers from ultra-short peptides using sortase(2017)14 cited
• → Inhibition of homotypic adhesion of T‐cells: secondary structure of an ICAM‐1‐derived cyclic peptide(1997)20 cited
• Synthesis and biological studies of cyclic peptides(2018)